Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2017 1
2018 1
2019 1
2020 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial.
Voors AA, Damman K, Teerlink JR, Angermann CE, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P; EMPULSE Trial Investigators. Voors AA, et al. Eur J Heart Fail. 2022 Oct;24(10):1844-1852. doi: 10.1002/ejhf.2681. Epub 2022 Sep 27. Eur J Heart Fail. 2022. PMID: 36066557 Free PMC article. Clinical Trial.
CONCLUSION: In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no longer evident after 90 days. Acute renal events were similar in both groups. ...
CONCLUSION: In patients hospitalized for acute heart failure, empagliflozin caused an early modest decline in renal function which was no lo …
A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease.
McGinley J, Thwaites R, Brebner W, Greenan-Barrett L, Aerssens J, Öner D, Bont L, Wildenbeest J, Martinón-Torres F, Nair H, Pollard AJ, Openshaw P, Drysdale S; REspiratory Syncytial virus Consortium in EUrope (RESCEU) Investigators. McGinley J, et al. J Infect Dis. 2022 Aug 12;226(Suppl 1):S117-S129. doi: 10.1093/infdis/jiab370. J Infect Dis. 2022. PMID: 34522970
RESULTS: RSV-specific antibody appears to protect from disease in mice, but such an effect was less evident in bovine RSV. Strong T-cell, Th1, Th2, Th17, CD4/CD8 responses, and weak Treg responses accompany severe disease in mice. ...
RESULTS: RSV-specific antibody appears to protect from disease in mice, but such an effect was less evident in bovine RSV. Strong T-c …
Short- and long-term effectiveness of a smartphone application for improving measures of adiposity: A randomised clinical trial - EVIDENT II study.
Gomez-Marcos MA, Patino-Alonso MC, Recio-Rodriguez JI, Agudo-Conde C, Romaguera-Bosch M, Magdalena-Gonzalez O, Gomez-Arranz A, Mendizabal-Gallastegui N, Angel Fernandez-Diez J, Gomez-Sanchez L, Maderuelo-Fernandez JA, Rodriguez-Sanchez E, Garcia-Ortiz L; on behalf the EVIDENT Investigators 11. Gomez-Marcos MA, et al. Eur J Cardiovasc Nurs. 2018 Aug;17(6):552-562. doi: 10.1177/1474515118761870. Epub 2018 Feb 28. Eur J Cardiovasc Nurs. 2018. PMID: 29488798 Clinical Trial.
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators. Simuni T, et al. Mov Disord. 2020 May;35(5):833-844. doi: 10.1002/mds.27989. Epub 2020 Feb 19. Mov Disord. 2020. PMID: 32073681 Free PMC article.
A previously reported more aggressive phenotype in GBA-PD is not evident early in the disease in N370s carriers. This observation identifies a window for potential disease-modifying interventions. ...TRIAL REGISTRATION: ClinicalTrials.gov (NCT01141023). 2020 The Authors. M …
A previously reported more aggressive phenotype in GBA-PD is not evident early in the disease in N370s carriers. This observation ide …
Using a smartphone app in changing cardiovascular risk factors: A randomized controlled trial (EVIDENT II study).
Gonzalez-Sanchez J, Recio-Rodriguez JI, Fernandez-delRio A, Sanchez-Perez A, Magdalena-Belio JF, Gomez-Marcos MA, Garcia-Ortiz L; On behalf the EVIDENT Investigators group. Gonzalez-Sanchez J, et al. Int J Med Inform. 2019 May;125:13-21. doi: 10.1016/j.ijmedinf.2019.02.004. Epub 2019 Feb 12. Int J Med Inform. 2019. PMID: 30914176 Clinical Trial.
Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium.
Phillips S, Schlenz AM, Mueller M, Melvin C, Adams RJ, Kanter J; (on behalf of the DISPLACE investigators). Phillips S, et al. Pediatr Blood Cancer. 2020 Nov;67(11):e28569. doi: 10.1002/pbc.28569. Epub 2020 Sep 7. Pediatr Blood Cancer. 2020. PMID: 32894002 Free PMC article.
PROCEDURE: A survey was administered to DISPLACE site principal investigators to identify current stroke prevention practices relative to the Stroke Prevention Trial in Sickle Cell Anemia (STOP) study protocols and the 2014 NHLBI guidelines. ...CONCLUSIONS: Guideline-based …
PROCEDURE: A survey was administered to DISPLACE site principal investigators to identify current stroke prevention practices relativ …
Intimal Flaps Detected by Optical Frequency Domain Imaging in the Proximal Segments of Native Coronary Arteries.
Muramatsu T, García-García HM, Onuma Y, Zhang YJ, Bourantas CV, Diletti R, Iqbal J, Radu MD, Ozaki Y, Serruys PW; on behalf of the TROFI investigators. Muramatsu T, et al. Circ J. 2013 Jun 15. Online ahead of print. Circ J. 2013. PMID: 23778184 Free article.
A total of 8,931 frames in 97 patients were analyzed in a frame-by-frame fashion (0.125-mm interval). OFDI identified 8 FS in 7 patients, none of which was evident angiographically. All FS were left untreated because the operators per protocol were blinded to the OFDI imag …
A total of 8,931 frames in 97 patients were analyzed in a frame-by-frame fashion (0.125-mm interval). OFDI identified 8 FS in 7 patients, no …
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators. Zhu JJ, et al. J Neurooncol. 2017 Dec;135(3):545-552. doi: 10.1007/s11060-017-2601-y. Epub 2017 Aug 28. J Neurooncol. 2017. PMID: 28849310 Free PMC article. Clinical Trial.
Initially, HRQoL improved in patients treated with TTFields/TMZ (CFB3: 24% and CFB6: 13%) versus TMZ (CFB3: -7% and CFB6: -17%), though this difference was no longer evident at the 9-month point. General scales, including physical and social functioning, showed no differen …
Initially, HRQoL improved in patients treated with TTFields/TMZ (CFB3: 24% and CFB6: 13%) versus TMZ (CFB3: -7% and CFB6: -17%), though this …